Cysteine cathepsins and extracellular matrix degradation.
暂无分享,去创建一个
[1] H. Genant,et al. The Effect of the Cathepsin K Inhibitor ONO‐5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] R. Chapurlat. Treatment of postmenopausal osteoporosis with odanacatib , 2014, Expert opinion on pharmacotherapy.
[3] D. Brömme,et al. The role of basic amino acid surface clusters on the collagenase activity of cathepsin K. , 2013, Biochemistry.
[4] C. Craik,et al. Elastin Degradation by Cathepsin V Requires Two Exosites* , 2013, The Journal of Biological Chemistry.
[5] Donald S. Williams,et al. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. , 2013, Bone.
[6] T. Livache,et al. Binding of chondroitin 4-sulfate to cathepsin S regulates its enzymatic activity. , 2013, Biochemistry.
[7] Marko Novinec,et al. Cathepsin K: a unique collagenolytic cysteine peptidase , 2013, Biological chemistry.
[8] J. Lindholt,et al. Plasma levels of cathepsins L, K, and V and risks of abdominal aortic aneurysms: a randomized population-based study. , 2013, Atherosclerosis.
[9] R. Veldhuizen,et al. Specific cleavage of the lung surfactant protein A by human cathepsin S may impair its antibacterial properties. , 2013, The international journal of biochemistry & cell biology.
[10] C. Zerbini,et al. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence , 2013, Therapeutic advances in musculoskeletal disease.
[11] D. Turk. MAIN software for density averaging, model building, structure refinement and validation , 2013, Acta crystallographica. Section D, Biological crystallography.
[12] L. V. Van Bortel,et al. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. , 2013, British journal of clinical pharmacology.
[13] K. Okumura,et al. Circulating cathepsin K as a potential novel biomarker of coronary artery disease. , 2013, Atherosclerosis.
[14] A. Dufour,et al. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. , 2013, Trends in pharmacological sciences.
[15] G. Fields. Interstitial Collagen Catabolism* , 2013, The Journal of Biological Chemistry.
[16] Bonnie F. Sloane,et al. The proinflammatory cytokines interleukin-1α and tumor necrosis factor α promote the expression and secretion of proteolytically active cathepsin S from human chondrocytes , 2013, Biological chemistry.
[17] B. Dardzinski,et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. , 2013, The Journal of clinical endocrinology and metabolism.
[18] Hongbin Li,et al. Effects of Cysteine Proteases on the Structural and Mechanical Properties of Collagen Fibers* , 2013, The Journal of Biological Chemistry.
[19] Chao-shu Tang,et al. Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. , 2012, Cardiovascular research.
[20] P. Saftig,et al. Effects of cathepsin K deficiency on intercellular junction proteins, luminal mucus layers, and extracellular matrix constituents in the mouse colon , 2012, Biological chemistry.
[21] M. Prata,et al. A shortcut to the lysosome: the mannose-6-phosphate-independent pathway. , 2012, Molecular genetics and metabolism.
[22] Takako Sasaki,et al. Cleavage of Nidogen-1 by Cathepsin S Impairs Its Binding to Basement Membrane Partners , 2012, PloS one.
[23] G. Bix,et al. Perlecan and the Blood-Brain Barrier: Beneficial Proteolysis? , 2012, Front. Pharmacol..
[24] C. Peters,et al. Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment , 2012, Inflammation Research.
[25] D. Zukor,et al. Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage , 2012, Arthritis Research & Therapy.
[26] D. Turk,et al. Protease signalling: the cutting edge , 2012, The EMBO journal.
[27] K. Okumura,et al. Role for Cysteine Protease Cathepsins in Heart Disease: Focus on Biology and Mechanisms With Clinical Implication , 2012, Circulation.
[28] A. Bradshaw. Diverse biological functions of the SPARC family of proteins. , 2012, The international journal of biochemistry & cell biology.
[29] G. Bix,et al. Oxygen–glucose deprivation (OGD) and interleukin-1 (IL-1) differentially modulate cathepsin B/L mediated generation of neuroprotective perlecan LG3 by neurons , 2012, Brain Research.
[30] X. Cheng,et al. Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis. , 2012, Arthritis and rheumatism.
[31] P. Libby,et al. Cathepsin K Deficiency Reduces Elastase Perfusion–Induced Abdominal Aortic Aneurysms in Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[32] M. Bogyo,et al. Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. , 2011, Current opinion in chemical biology.
[33] E. Brogi,et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.
[34] K. Okumura,et al. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. , 2011, Hypertension.
[35] Z. Werb,et al. Extracellular matrix degradation and remodeling in development and disease. , 2011, Cold Spring Harbor perspectives in biology.
[36] Alex Bateman,et al. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors , 2011, Nucleic Acids Res..
[37] Dipali Sharma,et al. Anti-cancer role of SPARC, an inhibitor of adipogenesis. , 2011, Cancer treatment reviews.
[38] O. Schilling,et al. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. , 2011, Journal of proteome research.
[39] Olga Vasiljeva,et al. Cysteine cathepsins: From structure, function and regulation to new frontiers☆ , 2011, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics.
[40] Ludovic C. Gillet,et al. Cysteine Cathepsins S and L Modulate Anti-angiogenic Activities of Human Endostatin* , 2011, The Journal of Biological Chemistry.
[41] M. Goldring,et al. Inflammation in osteoarthritis , 2011, Current opinion in rheumatology.
[42] Christoph Peters,et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. , 2011, Nature nanotechnology.
[43] M. Percival,et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. , 2011, Journal of autoimmunity.
[44] J. Joyce,et al. Proteolytic networks in cancer. , 2011, Trends in cell biology.
[45] B. Turk,et al. Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation. , 2011, Bioorganic & medicinal chemistry.
[46] Valerie M. Weaver,et al. The extracellular matrix at a glance , 2010, Journal of Cell Science.
[47] L. Holsinger,et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. , 2010, Biochimie.
[48] T. Reinheckel,et al. Specialized roles for cysteine cathepsins in health and disease. , 2010, The Journal of clinical investigation.
[49] C. Peters,et al. Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer , 2010, Biological chemistry.
[50] M. Bogyo,et al. Nuclear cysteine cathepsin variants in thyroid carcinoma cells , 2010, Biological chemistry.
[51] M. Percival,et al. Pharmacological Inhibition of Cathepsin S Decreases Atherosclerotic Lesions in Apoe-/- Mice , 2010, Journal of cardiovascular pharmacology.
[52] V. Turk,et al. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis , 2010, Biological chemistry.
[53] D. DeSimone,et al. The extracellular matrix in development and morphogenesis: a dynamic view. , 2010, Developmental biology.
[54] C. Peters,et al. Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis , 2010, Oncogene.
[55] J. Joyce,et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. , 2010, Genes & development.
[56] O. Vasiljeva,et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice , 2010, Proceedings of the National Academy of Sciences.
[57] Bonnie F. Sloane,et al. Interleukin-6 Increases Expression and Secretion of Cathepsin B by Breast Tumor-Associated Monocytes , 2010, Cellular Physiology and Biochemistry.
[58] G. Karsenty,et al. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms , 2009, Molecular and Cellular Endocrinology.
[59] J. Kos,et al. Versatile Loops in Mycocypins Inhibit Three Protease Families* , 2009, Journal of Biological Chemistry.
[60] O. Chinot,et al. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas , 2009, Acta Neuropathologica.
[61] P. Saftig,et al. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function , 2009, Nature Reviews Molecular Cell Biology.
[62] Bonnie F. Sloane,et al. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. , 2009, The American journal of pathology.
[63] M. Percival,et al. Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools , 2009, Biological chemistry.
[64] L. Duong,et al. Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies , 2009, Clinical pharmacology and therapeutics.
[65] L. Klareskog,et al. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. , 2009, European journal of pharmacology.
[66] C. Peters,et al. Cathepsin B release from rodent intestine mucosa due to mechanical injury results in extracellular matrix damage in early post-traumatic phases , 2009, Biological chemistry.
[67] V. Turk,et al. Lysosomes as “Suicide Bags” in Cell Death: Myth or Reality?* , 2009, The Journal of Biological Chemistry.
[68] D. Brömme,et al. Cathepsin K inhibitors for osteoporosis and potential off-target effects , 2009, Expert opinion on investigational drugs.
[69] J. Kos,et al. The role of cathepsin X in cell signaling , 2009, Cell adhesion & migration.
[70] I. Podgorski. Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? , 2009, Future medicinal chemistry.
[71] J. Pollard,et al. Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.
[72] O. Vasiljeva,et al. Autocatalytic processing of procathepsin B is triggered by proenzyme activity , 2009, The FEBS journal.
[73] M. James,et al. The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex. , 2008, Journal of molecular biology.
[74] R. Iozzo,et al. Diverse cell signaling events modulated by perlecan. , 2008, Biochemistry.
[75] R. Paridaens,et al. Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. , 2008, The International journal of biological markers.
[76] A. Pshezhetsky,et al. Caspase-3 Activation Triggers Extracellular Cathepsin L Release and Endorepellin Proteolysis* , 2008, Journal of Biological Chemistry.
[77] D. Brömme,et al. Regulation of cathepsin K activity by hydrogen peroxide , 2008, Biological chemistry.
[78] T. Welte,et al. Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis , 2008, Respiratory research.
[79] G. Salvesen,et al. Cysteine Cathepsins Trigger Caspase-dependent Cell Death through Cleavage of Bid and Antiapoptotic Bcl-2 Homologues* , 2008, Journal of Biological Chemistry.
[80] D. Zukor,et al. Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage. , 2008, The American journal of pathology.
[81] T. Peretz,et al. Cathepsin L Is Responsible for Processing and Activation of Proheparanase through Multiple Cleavages of a Linker Segment* , 2008, Journal of Biological Chemistry.
[82] F. Veillard,et al. Lung cysteine cathepsins: intruders or unorthodox contributors to the kallikrein-kinin system? , 2008, The international journal of biochemistry & cell biology.
[83] D. Turk,et al. Cystatins: biochemical and structural properties, and medical relevance. , 2008, Frontiers in bioscience : a journal and virtual library.
[84] J. Kos,et al. Cysteine protease cathepsin X modulates immune response via activation of β2 integrins , 2008, Immunology.
[85] Gillian Murphy,et al. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? , 2008, Nature Clinical Practice Rheumatology.
[86] C. F. van der Walle,et al. A heparin binding motif on the pro-domain of human procathepsin L mediates zymogen destabilization and activation. , 2008, Biochemical and biophysical research communications.
[87] K. Brix,et al. Cysteine cathepsins: cellular roadmap to different functions. , 2008, Biochimie.
[88] J. Falgueyret,et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.
[89] O. Vasiljeva,et al. Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. , 2008, Biochimie.
[90] B. Wiederanders,et al. Cathepsins B, K, and L Are Regulated by a Defined Collagen Type II Peptide via Activation of Classical Protein Kinase C and p38 MAP Kinase in Articular Chondrocytes* , 2008, Journal of Biological Chemistry.
[91] Raluca Ostafe,et al. Cathepsin B is essential for regeneration of scratch-wounded normal human epidermal keratinocytes. , 2007, European journal of cell biology.
[92] V. Turk,et al. Glycosaminoglycans Facilitate Procathepsin B Activation through Disruption of Propeptide-Mature Enzyme Interactions* , 2007, Journal of Biological Chemistry.
[93] Georges von Degenfeld,et al. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. , 2007, Nature chemical biology.
[94] D. Hanahan,et al. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. , 2007, Cancer research.
[95] Christoph Peters,et al. Cathepsin L Deficiency Reduces Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Knockout Mice , 2007, Circulation.
[96] E. Purisima,et al. The S2 subsites of cathepsins K and L and their contribution to collagen degradation , 2007, Protein science : a publication of the Protein Society.
[97] W. Stark,et al. Interaction between Human Cathepsins K, L, and S and Elastins , 2007, Journal of Biological Chemistry.
[98] Christopher M. Overall,et al. In search of partners: linking extracellular proteases to substrates , 2007, Nature Reviews Molecular Cell Biology.
[99] O. Vasiljeva,et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. , 2007, Current pharmaceutical design.
[100] E. Vuorio,et al. Role of cathepsin K in normal joints and in the development of arthritis. , 2007, Current drug targets.
[101] J. Joyce,et al. Cysteine Cathepsins and the Cutting Edge of Cancer Invasion , 2007, Cell cycle.
[102] S. Zahler,et al. RGD-dependent Binding of Procathepsin X to Integrin αvβ3 Mediates Cell-adhesive Properties* , 2006, Journal of Biological Chemistry.
[103] Bonnie F. Sloane,et al. Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.
[104] Karine Clément,et al. Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. , 2006, Endocrinology.
[105] B. Turk. Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.
[106] J. Kos,et al. Carboxypeptidase cathepsin X mediates beta2-integrin-dependent adhesion of differentiated U-937 cells. , 2006, Experimental cell research.
[107] O. Vasiljeva,et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. , 2006, Cancer research.
[108] Francesco Leonetti,et al. Substrate Profiling of Cysteine Proteases Using a Combinatorial Peptide Library Identifies Functionally Unique Specificities* , 2006, Journal of Biological Chemistry.
[109] B. Turk,et al. Cysteine cathepsins in the immune response. , 2006, Tissue antigens.
[110] R. Kalluri,et al. Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors* , 2006, Journal of Biological Chemistry.
[111] D. Hanahan,et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. , 2006, Genes & development.
[112] P. Libby,et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. , 2006, Atherosclerosis.
[113] M. Daemen,et al. Disruption of the Cathepsin K Gene Reduces Atherosclerosis Progression and Induces Plaque Fibrosis but Accelerates Macrophage Foam Cell Formation , 2005, Circulation.
[114] E. Vuorio,et al. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. , 2005, Arthritis and rheumatism.
[115] J. Falgueyret,et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. , 2005, Journal of medicinal chemistry.
[116] A. Rudensky,et al. The lysosomal cysteine proteases in MHC class II antigen presentation , 2005, Immunological reviews.
[117] T. Chambers,et al. Recent developments in cathepsin K inhibitor design. , 2005, Current opinion in drug discovery & development.
[118] D. Brömme,et al. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. , 2005, Advanced drug delivery reviews.
[119] J. Kos,et al. Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues. , 2005, Experimental cell research.
[120] L. Juliano,et al. Cathepsin X binds to cell surface heparan sulfate proteoglycans. , 2005, Archives of biochemistry and biophysics.
[121] Bonnie F. Sloane,et al. Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. , 2005, Seminars in cancer biology.
[122] Bonnie F. Sloane,et al. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells , 2005, Journal of Cell Science.
[123] Bonnie F. Sloane,et al. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. , 2005, Neoplasia.
[124] O. Vasiljeva,et al. Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans , 2005, FEBS letters.
[125] A. Baici,et al. Cathepsin B in osteoarthritis: uncontrolled proteolysis in the wrong place. , 2004, Seminars in arthritis and rheumatism.
[126] Matthew Bogyo,et al. Cathepsin V, a Novel and Potent Elastolytic Activity Expressed in Activated Macrophages* , 2004, Journal of Biological Chemistry.
[127] R. Weissleder,et al. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. , 2004, Arthritis and rheumatism.
[128] P. Libby,et al. Lysosomal Cysteine Proteases in Atherosclerosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[129] T. Welte,et al. Pivotal role of cathepsin K in lung fibrosis. , 2004, The American journal of pathology.
[130] Q. Deveraux,et al. Comprehensive search for cysteine cathepsins in the human genome , 2004, Biological chemistry.
[131] E. Vuorio,et al. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis , 2004, Annals of the rheumatic diseases.
[132] D. Hanahan,et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.
[133] M. Bogyo,et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. , 2004, Molecular cell.
[134] M. Bogyo,et al. Regulation of Collagenase Activities of Human Cathepsins by Glycosaminoglycans* , 2004, Journal of Biological Chemistry.
[135] D. Brömme,et al. Production and activation of recombinant papain-like cysteine proteases. , 2004, Methods.
[136] O. Vasiljeva,et al. Recombinant human cathepsin H lacking the mini chain is an endopeptidase. , 2003, Biochemistry.
[137] M. Juliano,et al. Probing cathepsin K activity with a selective substrate spanning its active site. , 2003, Biochemical Journal.
[138] Bonnie F. Sloane,et al. Cathepsin B and its role(s) in cancer progression. , 2003, Biochemical Society symposium.
[139] Bonnie F. Sloane,et al. Functional imaging of proteolysis: stromal and inflammatory cells increase tumor proteolysis. , 2003, Molecular imaging.
[140] D. Brömme,et al. Cleavage Site Specificity of Cathepsin K toward Cartilage Proteoglycans and Protease Complex Formation , 2003, Biological chemistry.
[141] F. Gauthier,et al. Procongopain from Trypanosoma congolense Is Processed at Basic pH: An Unusual Feature among Cathepsin L-Like Cysteine Proteases , 2003, Biological chemistry.
[142] J. Deussing,et al. Thyroid functions of mouse cathepsins B, K, and L. , 2003, The Journal of clinical investigation.
[143] S. Goldring,et al. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. , 2003, Rheumatology.
[144] Makoto Naito,et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.
[145] Kenneth M. Yamada,et al. Fibronectin at a glance , 2002, Journal of Cell Science.
[146] Bonnie F. Sloane,et al. Degradation of Extracellular Matrix Protein Tenascin-C by Cathepsin B: An Interaction Involved in the Progression of Gliomas , 2002, Biological chemistry.
[147] B. Gelb,et al. Collagenase Activity of Cathepsin K Depends on Complex Formation with Chondroitin Sulfate* , 2002, The Journal of Biological Chemistry.
[148] G. Salvesen,et al. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. , 2002, Current pharmaceutical design.
[149] J. Kos,et al. Lysosomal Enzymes, Cathepsins in Brain Tumour Invasion , 2002, Journal of Neuro-Oncology.
[150] S. Santavirta,et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. , 2002, Arthritis and rheumatism.
[151] S. Goldring,et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. , 2002, Arthritis and rheumatism.
[152] S. Pervaiz,et al. A permissive apoptotic environment: function of a decrease in intracellular superoxide anion and cytosolic acidification. , 2002, Biochemical and biophysical research communications.
[153] A. Burlingame,et al. Chemical Approaches for Functionally Probing the Proteome* , 2002, Molecular & Cellular Proteomics.
[154] D Lamba,et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases , 2001, The EMBO journal.
[155] R. Gordon,et al. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. , 2001, The American journal of pathology.
[156] D. Turk,et al. Lysosomal cysteine proteases: facts and opportunities , 2001, The EMBO journal.
[157] E. Vuorio,et al. Accelerated Turnover of Metaphyseal Trabecular Bone in Mice Overexpressing Cathepsin K , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[158] I. James,et al. Biosynthesis and processing of cathepsin K in cultured human osteoclasts. , 2001, Bone.
[159] V. Turk,et al. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing. , 2001, Biochemistry.
[160] L. Juliano,et al. Cathepsin B Activity Regulation , 2001, The Journal of Biological Chemistry.
[161] V. Herzog,et al. Cysteine Proteinases Mediate Extracellular Prohormone Processing in the Thyroid , 2001, Biological chemistry.
[162] Roger Y. Tsien,et al. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis , 2000, Nature Cell Biology.
[163] Bonnie F. Sloane,et al. Human Procathepsin B Interacts with the Annexin II Tetramer on the Surface of Tumor Cells* , 2000, The Journal of Biological Chemistry.
[164] H. Ploegh,et al. Secreted cathepsin L generates endostatin from collagen XVIII , 2000, The EMBO journal.
[165] D. Turk,et al. Lysosomal cysteine proteases: more than scavengers. , 2000, Biochimica et biophysica acta.
[166] D. Turk,et al. Crystal structure of cathepsin X: a flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease. , 2000, Structure.
[167] J. Kos,et al. Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking , 2000, British Journal of Cancer.
[168] D. Brömme,et al. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. , 2000, Biochemistry.
[169] V. Turk,et al. Autocatalytic processing of recombinant human procathepsin B is a bimolecular process , 1999, FEBS letters.
[170] I. Kola,et al. Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[171] E. Purisima,et al. Human cathepsin X: A cysteine protease with unique carboxypeptidase activity. , 1999, Biochemistry.
[172] E. Mehler,et al. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. , 1999, Biochemistry.
[173] P. Delmas,et al. The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases* , 1998, The Journal of Biological Chemistry.
[174] Sheila J. Jones,et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[175] J. Mort,et al. Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. , 1998, Biochemical Journal.
[176] J. Kos,et al. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). , 1998, Oncology reports.
[177] P. Petrow,et al. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. , 1998, The Journal of rheumatology.
[178] P. Libby,et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.
[179] R. Desnick,et al. Genomic structure, chromosomal localization, and expression of human cathepsin W. , 1998, Biochemical and biophysical research communications.
[180] A. Hollander,et al. Molecular Interaction and Matrix Assembly , 1998, The Biochemical journal.
[181] J. Kos,et al. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. , 1998, Biological chemistry.
[182] D. Turk,et al. Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. , 1998, Structure.
[183] Z. Werb. ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.
[184] R. Ménard,et al. Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. , 1997, Biochemistry.
[185] D. Turk,et al. Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen. , 1997, Journal of molecular biology.
[186] G. Huet,et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. , 1997, British journal of rheumatology.
[187] R. Baumgrass,et al. Identification of Peptide Fragments Generated by Digestion of Bovine and Human Osteocalcin with the Lysosomal Proteinases Cathepsin B, D, L, H, and S , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[188] C. Debouck,et al. Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts (*) , 1996, The Journal of Biological Chemistry.
[189] D. Mcnulty,et al. Proteolytic Activity of Human Osteoclast Cathepsin K , 1996, The Journal of Biological Chemistry.
[190] D. Brömme,et al. Human Cathepsin O2, a Matrix Protein-degrading Cysteine Protease Expressed in Osteoclasts , 1996, The Journal of Biological Chemistry.
[191] E. Kominami,et al. Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. , 1995, Biochemical and biophysical research communications.
[192] J. Kos,et al. Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. , 1995, Biological chemistry Hoppe-Seyler.
[193] D. Turk,et al. Human cathepsin B is a metastable enzyme stabilized by specific ionic interactions associated with the active site. , 1994, Biochemistry.
[194] H. Kobayashi,et al. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. , 1993, Biochimica et biophysica acta.
[195] T. Chambers,et al. Degradation of bone matrix proteins by osteoclast cathepsins. , 1993, The International journal of biochemistry.
[196] V. Turk,et al. Kinetics of the pH-induced inactivation of human cathepsin L. , 1993, Biochemistry.
[197] R. Mason,et al. Surface activation of pro-cathepsin L. , 1992, Biochemical and biophysical research communications.
[198] T. Hardingham,et al. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. , 1992, The Journal of biological chemistry.
[199] Bonnie F. Sloane,et al. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. , 1992, The Biochemical journal.
[200] Robert Huber,et al. The refined 2.15 A X‐ray crystal structure of human liver cathepsin B: the structural basis for its specificity. , 1991, The EMBO journal.
[201] H. Kirschke,et al. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. , 1989, The Biochemical journal.
[202] Bonnie F. Sloane,et al. Membrane-associated cathepsin L: a role in metastasis of melanomas. , 1989, Biochemical and biophysical research communications.
[203] J. Peter-Katalinic,et al. Human cathepsin B and cysteine proteinase inhibitors (CPIs) in inflammatory and metabolic joint diseases. , 1988 .
[204] R. Maciewicz,et al. Collagenolytic cathepsins of rabbit spleen: a kinetic analysis of collagen degradation and inhibition by chicken cystatin. , 1987, Collagen and related research.
[205] Bonnie F. Sloane,et al. Cathepsin B: association with plasma membrane in metastatic tumors. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[206] A. Poole,et al. Extracellular presence of the lysosomal proteinase cathepsin B in rheumatoid synovium and its activity at neutral pH. , 1984, Arthritis and rheumatism.
[207] Bonnie F. Sloane,et al. Lysosomal cathepsin B: correlation with metastatic potential. , 1981, Science.
[208] A. Berger,et al. On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.
[209] G. Shi,et al. Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms. , 2013, Future cardiology.
[210] B. Turk,et al. The endolysosomal system in cell death and survival. , 2013, Cold Spring Harbor perspectives in biology.
[211] D. Brömme,et al. Role of Cysteine Cathepsins in Extracellular Proteolysis , 2011 .
[212] K. McCoy,et al. Cytokines regulate cysteine cathepsins during TLR responses. , 2011, Cellular immunology.
[213] BMC Biochemistry BioMed Central , 2009 .
[214] Sanjay Kumar,et al. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents. , 2004, Progress in medicinal chemistry.
[215] J R Griffiths,et al. Causes and consequences of tumour acidity and implications for treatment. , 2000, Molecular medicine today.
[216] B. Bresnihan,et al. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. , 1999, Rheumatology.
[217] D. Turk,et al. Revised Definition of Substrate Binding Sites of Papain-Like Cysteine Proteases , 1998, Biological chemistry.
[218] V. Turk,et al. Determination of Cathepsins B and H in Sera and Synovial Fluids of Patients with Different Joint Diseases , 1990, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.